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ABSTRACT
Background: We have previously found a 28% reduction in common cold incidence 
with 50 mg/day vitamin E supplementation in a subgroup of the Alpha-Tocopherol Beta-Carotene 
Cancer Prevention (ATBC) Study cohort: older city-dwelling men (≥65 years) who smoked 
only 5–14 cigarettes/day.
Objective: To carry out more detailed analyses to explore the modification of vitamin E 
effect by age, smoking, and residential neighborhood.
Methods: We examined the effect of vitamin E on common cold risk in subjects consisting 
of the placebo and vitamin E arms (n = 14,573) of the ATBC Study, which recruited males 
aged 50–69 years who smoked ≥5 cigarettes/day at the baseline. The ATBC Study was conducted 
in southwestern Finland in 1985–1993; the active follow-up lasted for 4.7 years (mean). 
We modeled common cold risk as a function of age-at-follow-up in the vitamin E arm 
compared with the placebo arm using linear splines in Poisson regression.
Results: In participants of 72 years or older at follow-up, the effect of vitamin E diverged. 
Among those smoking 5–14 cigarettes per day at baseline and living in cities, vitamin E 
reduced common cold risk (RR = 0.54; 95% CI 0.37–0.80), whereas among those smoking 
more and living away from cities, vitamin E increased common cold risk (RR = 1.58; 1.23–2.01).
Conclusions: Vitamin E may cause beneficial or harmful effects on health depending on 
various modifying factors. Accordingly, caution should be maintained in public health 
recommendations on vitamin E supplementation until its effects are better understood.
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INTRODUCTION
Animal studies have found that vitamin E may affect susceptibility to and severity of 
diverse viral and bacterial respiratory infections (1-5). Although several studies found 
that vitamin E may have beneficial effects on various laboratory measures of the immune 
system in animals and humans (5,6), harmful effects on the immune system have also 
been reported (7,8). Two animal studies found positive effects on the immune system 
with moderate vitamin E doses, but adverse effects with large doses (9,10).
Only a few trials have examined the effect of vitamin E supplementation on clinical 
infectious disease outcomes, such as respiratory and urinary tract infections (5,11-15) 
and tuberculosis (16) in human subjects. On the whole, these trials found no unequivocal 
benefit from vitamin E and, paradoxically, one trial found an increase in the severity 
of acute respiratory illness with 200 mg per day of vitamin E (12). Three trials examined 
the effect of vitamin combinations containing vitamin E on respiratory infections; 
however, no specific conclusions of vitamin E can be drawn of these trials (17-19).
We previously found no overall effect on common cold risk with 50 mg per day of 
vitamin E in the Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) Study (20).
However, in a small subgroup of older city-dwelling men (≥65 years) who smoked only 
5–14 cigarettes per day, vitamin E supplementation was associated with a statistically 
highly significant, but quantitatively modest, reduction in common cold incidence 
(RR = 0.72; 95% CI: 0.62–0.83) (20). Whether this observation resulted from 
a physiological effect or emerged by chance from a series of subgroup analyses 
remained an open question. Since the number of common cold episodes recorded 
in the ATBC Study was very high, we carried out more detailed analyses to explore 




Study Participants and Intervention Groups
The design and methods of the ATBC Study examining the effects of vitamin E (dl-α-tocopheryl acetate (AT), 
50 mg/day) and β-carotene (BC, 20 mg/day) on the incidence of lung cancer and other cancers have already been 
described in detail (20,21). In brief, the trial participants were recruited in 1985–88 from the total male population 
aged 50–69 years living in southwestern Finland (n = 290,406). To be eligible, participants had to smoke ≥5 cigarettes 
per day at entry. The eligible participants (n = 29,133) were randomized to one of four intervention arms and 
administered placebo, AT, BC, or AT + BC. The planned intervention continued for 5 to 8 years (median 6.1 years) 
until April 30, 1993, with 3 follow-up visits annually, but because of deaths and drop-outs the active follow-up lasted 
for 4.7 years (mean). The trial was approved by the institutional review boards of the participating institutions; 
all participants gave written informed consent. At baseline, prior to randomization, the men completed a questionnaire 
on their medical and smoking histories and general background characteristics. In the current analysis we excluded 
participants who were administered β-carotene to avoid any problems caused by potential interaction between 
vitamin E and β-carotene, so that we restricted ourselves to the placebo and AT arms of the trial (n = 14,573; Table 1).
Outcome Definition and Smoking Status Evaluation during Follow-Up
At each follow-up visit to the local study center, 3 times per year with 4-month intervals (Table 1), the participant was 
asked "Have you had a common cold since the previous visit, and if so, how many times?" The occurrence of "other 
upper respiratory tract infection" and "acute bronchitis" was also asked about. The number of colds reported at each 
follow-up visit was used as the outcome for this study. This outcome, self-reported colds, is based on subjective 
symptoms and not on any laboratory findings. However, since it is the subjective symptoms that lead a person to seek 
medical attention and obtain sick-leave, in this respect the subjective outcome is most relevant for public health 
purposes. The manifestations of the common cold are so typical that self-diagnosis by the patient is usually correct (22).
During 69,094 person-years of active follow-up covered by visits to the study centers, 55,770 common cold episodes 
were recorded.
At each follow-up visit, the participant was asked: "Have you been smoking since the previous visit?" with the 
following alternative responses provided: 1) no, 2) yes, but now I have quit, 3) yes, continuously (Table 1). In this study
we used responses 1) and 3) when exploring the effect of smoking cessation before the follow-up visit.
Statistical Methods
Because we analyzed the modification of vitamin E effect by age, and the ATBC Study lasted for some 6 years, 
in the current analyses we used the age of participant at the follow-up visit. This is the biological age at the point 
of time when the outcome for the preceding 4-month period is evaluated.
The number of common cold episodes was modeled using Poisson regression. The risk ratio (RR) and the likelihood 
ratio-based 95% confidence interval (95% CI) were calculated using the SAS PROC GENMOD program (release 8.1, 
SAS Institute, Inc., Cary, NC). Linear spline-modeling (23) was carried out for the four groups defined by baseline 
smoking and residential neighborhood as follows.
First, using a base model containing the mean vitamin E-effect, and a linear trend to adjust for the average reduction 
in common cold incidence with age, we added ten linear splines to both trial arms at 2 year-intervals starting 
at 52 years of age-at-follow-up. Thereafter, linear spline terms for the vitamin E arm were added to the same knots, 
and the statistical significance of the vitamin E—age-at-follow-up interaction was calculated from the change in the 
–2 × Log(Likelihood) difference. This saturated model was simplified by dropping the knots that had the least effect on 
the vitamin E spline model, starting with those with the lowest Wald-test χ2 value. The corresponding knots covering 
both arms were concurrently dropped out. The models were simplified until all remaining vitamin E arm knots gave 
a significant contribution to the spline model (χ2 > 4). Thus, the final model contained knots at the same years for 
both arms to provide the baseline, and for the vitamin E arm to provide the age-modification. Visually, the final 
models captured all the main features of the saturated models (graphs for saturated models not shown). The optimized 
models are described in Table 2 and the corresponding graphs in Fig. 1. Two-tailed p-values were used.
We tested the modifying effect of residential neighborhood on the vitamin E effect separately in participants who 
smoked 5–14 and those who smoked ≥15 cigarettes per day. Based on the appearance of the spline curves (Fig. 1), 
we restricted this analysis to participants aged ≥62 and ≥65 years at the follow-up visit, respectively, in the light and 
heavy smokers. First we added a linear trend to adjust for the average reduction in common cold incidence with age, 
the mean vitamin E-effect, mean effect of residential neighborhood, and a linear spline to the vitamin E arm at 62 or 65 
years. To test the role of residential neighborhood, we further added the mean vitamin E effect and a linear spline to 
the vitamin E arm to the city-dwellers. The change in the –2 × Log(Likelihood) gives χ2(2 df), which was used to 
calculate the p[2-tail]-value to test the role of residential neighborhood in the vitamin E spline-models.
As to supplementation, the analyses were carried out following the intention-to-treat principle. Compliance with 
supplementation was high: some 80% of participants took more than 95% of their prescribed capsules during their 
active participation in the trial; there were no differences in capsule consumption among the intervention groups (21). 
The outcome was, however, available only for those participants who continued with the trial and participated in 
the follow-up visits.
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Table 1. Baseline Characteristics of Participants, and the Age and Smoking Status at Follow-Up 
Visits, The ATBC Study 1985–1993; No β-Carotene Participants
Baseline characteristics No. of
participants









Age of smoking initiation*
<21 years 10,842 (74%)
≥21 years 3,727 (26%)
Residential neighborhood during 
the last 20 years*




Follow-up visit variables No. of visits
All visits 207,284 (100%)














Smoking since the previous visit 
No 23,032 (11%)
Yes, but quit before current visit 5,817 (3%)
Yes, continuously 178,433 (86%)
* Data on residential neighborhood was missing from 2 participants, 
and on age at smoking initiation from 4 participants.
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Table 2. Optimizing the Spline Models for the Age-Modification 
of Vitamin E Effect on Common Cold Incidence
Group Saturated model* Simple model*
≥15 cigarettes per day χ2(10 df) = 40.9 χ2(4 df) = 36.5
living away from cities p = 0.0000002
knots at 52, 56, 58, 68 yrs
≥15 cigarettes per day χ2(10 df) = 17.3 χ2(2 df) = 7.8
living in a city p = 0.02
knots at 64, 66 yrs
5–14 cigarettes per day χ2(10 df) = 22.3 χ2(1 df) = 18.9
living away from cities p = 0.00002
knot at 56 yrs
5–14 cigarettes per day χ2(10 df) = 46.5 χ2(2 df) = 38.7
living in a city p = 0.000000004
knots at 60, 62 yrs
* The χ2 measures the improvement in the Poisson model when the knots indicated 
are added to the vitamin E arm in the simple model. 
In the saturated model, 10 knots at 2-year intervals were added, starting at 52 years. 
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RESULTS
Table 1 shows the distributions for the baseline data for age, smoking level, age of smoking 
initiation, residential neighborhood, and follow-up data for age and smoking at the follow-up 
visits. On average, 0.27 common cold episodes were reported at each four-monthly follow-up 
visit, corresponding to an annual rate of 0.8 cold episodes.
There is no overall effect, with a narrow confidence interval, of vitamin E supplementation in 
the four groups defined by baseline smoking and residential neighborhood (Table 3). To examine 
the potential modification of vitamin E effect by age, we constructed linear spline models 
for the vitamin E effect as a function of age-at-follow-up separately for the four groups defined 
by baseline smoking and residential neighborhood. These groups show statistically highly 
significant modification of vitamin E effect by age-at-follow-up, except for city-dwellers 
smoking ≥15 cigarettes per day (Fig. 1, Table 2).
Fig. 1. The effect of vitamin E on the relative risk of
common cold as a function of age at follow-up.
Participants smoking more (A) and less (B) are further
divided into subgroups by residential neighborhood.
RR indicates the relative risk of colds between the
vitamin E and placebo arms. See Table 2 for the
description of the statistical models.
See Fig. 1. redrawn in 2014 at the end of this paper.
Among participants who smoked ≥15 cigarettes 
per day at baseline, the spline curve of vitamin E
effect shows a trend towards harm for old
participants (Fig. 1A). Among the heavy 
smokers living away from cities, there is 
a peak of increased risk at 56 years of age.
Although there is no apparent biological 
rationale for such a sharp peak in the common
cold risk, dropping out the knots at 52, 56, 
and 58 years would reduce the χ2 value 
by 17.9 (3 df; p = 0.0005) so that these 
knots are retained in the spline model.
Among participants who smoked only 5–14 cigarettes per day at baseline, the spline curves suggest 
slight harm for young participants, but there is an age-dependent trend towards benefit in old 
participants (Fig. 1B). Among the city-dwellers who smoke less, there is a peak indicating harm at 
about 62 years of age. Although there is no apparent biological rationale for such a sharp peak here 
either, omitting the knot at 62 years reduces the χ2 value by 16.3 (1 df; p = 0.0001); therefore both 
knots are retained in the spline model. The knot at 56 years in the participants smoking less, who 
live away from cities, remained after the stepwise reduction of the spline model, but there was no 
meaningful difference compared with spline models with a single knot located at 52, 54 or 58 years.
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Because this work was motivated by the effect of vitamin E observed in the subgroup 
of ≥65 year old city-dwellers who smoked 5–14 cigarettes per day (20) and inclusion of that 
subgroup in the vitamin E spline model does not provide a test independent of the original 
finding, we examined whether age is a modifier outside of this small subgroup. When the 
participants aged ≥65 years at baseline were excluded from the spline model of the city-dwellers 
who smoked 5–14 cigarettes per day at baseline, the vitamin E spline model was still highly 
significant (χ2[2 df] = 12.3, p = 0.002). The other three of the four subgroups test the 
age-modification of vitamin E effect independently of the original hypothesis-generating 
subgroup (Table 2).
Among the oldest participants, the effect of vitamin E on common cold incidence substantially 
diverges in the light and heavy smokers, but the role of residential neighborhood is less evident 
(Fig. 1). Therefore we tested whether including the residential neighborhood significantly 
improves the vitamin E spline models at the upper age range. Among participants who smoked 
5–14 cigarettes per day there was strong evidence that the age at visit of 62 years or more modifies 
the vitamin E effect differently in city-dwellers and those who live away from cities (p = 0.018). 
In contrast, for those who smoked ≥15 cigarettes per day there was weaker evidence that 
the age at visit of 65 years or more modifies the vitamin E effect differently in the residential 
neighborhood groups (p = 0.042).
Based on the appearance of the spline curves, certain age-ranges were selected for explicit 
calculation of the effect estimate of vitamin E supplementation and its confidence interval 
(Fig. 1, Table 3). Vitamin E supplementation for participants smoking less was associated with 
a significant increase in the risk of colds at 50–56 years in those who live away from cities, 
and at 61–63 years in the city-dwellers. For city-dwellers who smoke less, vitamin E 
supplementation caused a substantial reduction in the risk of colds for participants aged 
69 years or more, but the benefit was smaller among participants living away from cities. 
Among the heavy smokers, vitamin E supplementation significantly increased the risk of 
colds among the oldest participants (Table 3).
It is noteworthy that among the ≥72 year old participants the greatest benefit was seen in 
city-dwellers smoking 5–14 cigarettes per day, whereas the greatest harm was seen in the mirror 
image, i.e., participants living outside cities and smoking ≥15 cigarettes per day (Fig. 1, Table 3). 
The confidence intervals for the vitamin E effect on these two groups are strikingly different. 
It is also noteworthy that in both of these groups there is a peak of harm at 62 and 54 years 
respectively, whereas the remaining two groups do not show comparable peaks for the younger 
participants.
The preceding analysis is based on defining the subgroups by smoking level at baseline. 
To explore whether other measures of cigarette smoke exposure would further modify 
the effect of vitamin E, we analyzed the risk of colds in participants aged ≥72 years by combining 
the residential neighborhood groups, but keeping the baseline low and heavy smoking groups 
separate. Among the old participants who smoked heavily at baseline, the vitamin E effect 
is significantly modified by the age of smoking initiation (Table 4). In these heavy smokers, 
there was no definite evidence of harm from vitamin E in those who quit smoking before the visit, 
but the number of quitters is low. Among participants who smoked less at baseline, 
age of smoking initiation did not modify the vitamin E effect, and smoking cessation 
did not lead to a greater vitamin E benefit (Table 4).
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Table 3. The Effect of Vitamin E Supplementation on the Risk of the Common Cold 
in Selected Age-Groups by Baseline Smoking and Residential Neighborhood
≥15 cigarettes per day 5–14 cigarettes per day 
Town, village, City Town, village, City 
or countryside or countryside 
Number of participants: 6,587 5,074 1,751 1,159
All visits (207,270 visits) 
RR 0.98 1.00 1.02 1.02
95% CI 0.95–1.01 0.97–1.03 0.97–1.08 0.96–1.08 
Age at visit  
50–56 yrs (62,054 visits)
RR 1.01 0.98 1.20 1.07
95% CI 0.96–1.05 0.93–1.03 1.08–1.32 0.96–1.20
61–63 yrs (35,182 visits)
RR 0.93 1.02 0.97 1.30
95% CI 0.87–0.99 0.95–1.10 0.86–1.09 1.13–1.50 
69–71 yrs (11,321 visits)
RR 1.11 1.04 0.80 0.68
95% CI 0.98–1.27 0.90–1.19 0.67–0.96 0.54–0.84 
72–77 yrs (3,717 visits)
RR 1.58 1.35 0.90 0.54
95% CI 1.23–2.01 1.03–1.76 0.63–1.28 0.37–0.80 
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Table 4. Modification of Vitamin E Effect on Common Cold Risk 
by Age at Smoking Initiation and by Recent Smoking 
among Participants Aged 72 Years or More at the Follow-Up Visit
Risk of colds in Test of
the vitamin E arm interaction
RR; 95% CI p
Baseline smoking ≥15 cigarettes per day
All in the subgroup (2,513 visits) 1.42; 1.18–1.70
Age at smoking initiation
<21 years (1,482 visits) 1.68; 1.34–2.12 0.02
≥21 years (1,031 visits) 1.09; 0.82–1.45
Smoking at follow-up
Continued (1,992 visits) 1.48; 1.21–1.80 0.10
Quit (444 visits) 0.96; 0.59–1.55
Baseline smoking 5–14 cigarettes per day
All in the subgroup (1,204 visits) 0.71; 0.54–0.91
Age at smoking initiation
<21 years (578 visits) 0.67; 0.45–0.98 0.6
≥21 years (626 visits) 0.75; 0.53–1.06
Smoking at follow-up
Continued (788 visits) 0.62; 0.45–0.87 0.12
Quit (368 visits) 0.98; 0.61–1.55
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DISCUSSION
In a previous paper we reported a 28% reduction in common cold incidence with vitamin E 
supplementation in older city-dwelling men who smoked only 5–14 cigarettes per day (20). 
The present work was carried out to analyze whether the three characteristics specifying 
the small subgroup, i.e., age, smoking, and residential neighborhood, would cause a more general 
modification of the vitamin E effect. The current spline model analyses over age-at-follow-up 
seem to show that the reduction of common cold incidence with vitamin E in the previously 
identified small subgroup (20) is explained by its physiological effects rather than by a chance 
occurrence emerging from a series of subgroup analyses.
Age and smoking are plausible modifying factors for the effect of vitamin E on common cold 
incidence, but a biological rationale for the role of residential neighborhood as a modifying factor 
is not as apparent. Possibly higher level of air pollution or much more frequent use of public 
transport with concomitant exposure to infectious agents could explain the observed difference 
between cities and smaller communities.
Recently, a small trial with 617 elderly participants in long-term care facilities found a slightly 
lower incidence of colds among participants administered 200 mg per day of vitamin E 
(RR = 0.83; 95% CI: 0.68–1.01) (13). Another small trial with 652 elderly noninstitutionalized 
people found a slightly higher incidence of respiratory infection among participants administered 
200 mg per day of vitamin E (RR = 1.12; 0.88–1.25), and a statistically significant increase in 
symptom severity, fever and restriction in activity (12). Although such divergence may result 
from the small size of the trials, it might also result from biological heterogeneity, as we found 
both increases and decreases in common cold risk with 50 mg per day of vitamin E supplementation
in our current study, depending on the characteristics of the subgroup.
We found quite sharp peaks of increase in common cold risk at 54 and 62 years with vitamin E 
supplementation in two of our four subgroups (Fig. 1), both highly unlikely to be due to chance, 
although there is no apparent biological rationale for such peaks. Possibly the peaks may be related 
to social factors such as retirement, which in Finland occurs usually at about 58 to 60 years; 
however, retirement does not occur as such a sharp peak as seen in the spline models. 
The modification of the vitamin E effect on the common cold risk by age, smoking, and residential 
neighborhood may be of more general interest as regards the physiological effects of antioxidants. 
There is evidence indicating that free radical production may be important in the emergence 
of various chronic diseases such as cancer and cardiovascular diseases (24,25) as well as 
in the pathogenesis of certain viral and bacterial diseases (26–28). It is sometimes assumed 
that antioxidants, including vitamin E, might have a consistent unidirectional broad-spectrum 
benefit on the human system by protecting it against the free radicals (24,25). Our finding that 
vitamin E supplementation significantly increases or decreases common cold risk depending 
on the three variables in question is inconsistent with the notion of uniform benefits from 
antioxidant supplementation.
In the current work we had available a very large number of outcomes (55,770 episodes of the 
common cold) which rendered it possible to analyze the age-dependence of the vitamin E effect 
in the four subgroups accurately. With severe diseases such as cancers or cardiovascular diseases, 
the statistical power is usually too small to permit analyses similar to the current spline models. 
Still, it is possible that comparable effect-modification occurs in the case of more serious diseases, 
even though directly extrapolating the particular modifying factors observed in this work to any 
other diseases is not justified. In a previous analysis of the ATBC Study cohort, we found that the 
effect of vitamin E on the risk of pneumonia was modified by the age of smoking initiation so that 
vitamin E reduced pneumonia risk in participants who began smoking at a later age, whereas 
vitamin E slightly increased the risk among participants who began smoking at an early age (14) 
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(see also Table 4). Thus, our findings for pneumonia risk also suggest substantial heterogeneity 
between population groups in the effects of vitamin E supplementation.
A recent meta-analysis focusing on the potential harm of vitamin E supplementation found 
that, starting from approximately 150 mg/day of vitamin E, there was increased mortality 
among people supplemented with vitamin E (29). However, it is possible that there is biological 
heterogeneity between population groups, so that people’s characteristics may determine 
whether vitamin E supplementation caused net benefit or harm. In our current study, the vitamin E 
dose was 50 mg/day, which is substantially less than the estimated threshold level in the 
above-mentioned meta-analysis (29); however, our current analyses on common cold incidence and 
our previous analyses on pneumonia incidence make it seem probable that some population groups 
are harmed at levels of 50 mg/day, even though the same low dose seems beneficial for other 
population groups (14,15). Thus, it may be unjustifiable to assume that there is a single threshold 
level for harmful effects that is valid for the entire population. Another recent review on vitamin E 
safety concluded that supplements appear harmless for most adults in amounts up to 1 g/day (30), 
whereas our subgroup analyses indicate harmful effects on restricted population groups at doses as 
low as 50 mg/day (Tables 3 and 4).
The definition of a common cold episode in our study was based on self-diagnosis, which is 
usually reliable (22). Although subjective perception of what is classified as a cold varies 
between participants, such inaccuracy in outcome assessment does not lead to consistent 
differences between our double-blinded study arms; rather, the inaccuracy renders the differences 
smaller than they may actually be. Our implicit assumption in this work was that the effect 
of vitamin E is based on its reported effects on the immune system (5,6), but even if the mechanism 
of the effect of vitamin E would be on other factors that determine whether a person has subjective 
symptoms of the common cold, the conclusions of our double-blind trial are not affected. 
Furthermore, even though a proportion of the self-reported colds may be caused by non-infectious 
etiology, this does not affect the validity of our observation that this common set of symptoms 
seems to be affected differently with vitamin E in different subgroups of people.
The modification of the vitamin E effect on common cold risk also bears on the heterogeneity 
of findings in common cold trials examining vitamin C, the major water-soluble antioxidant, 
which interacts with lipid-soluble vitamin E (5,31,32). The largest vitamin C trials found no effect 
on the risk of the common cold; however, low dietary vitamin C intake and acute physical stress 
were proposed as modifying factors that may explain statistically significant reduction in common 
cold risk with vitamin C supplementation in several small trials (5,33,34). Thus, it seems possible 
that these two closely related antioxidants, vitamin E and vitamin C, may affect common cold risk 
in restricted groups of people, even though there seems to be no overall effect in the general 
Western population. 
The main finding of our study is that vitamin E supplementation may cause benefit or harm 
to health depending on several modifying factors. It is premature to draw any practical conclusions 
from our study except that general caution should be maintained in public health recommendations 
on vitamin E supplementation until the effects of this vitamin are better understood. The possibility 
that vitamin E may reduce the risk of the ubiquitous common cold infection by half in some groups 
of elderly people would seem to warrant further study to define more precisely the population 
groups that might benefit from supplementation.
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Fig. 1. The effect of vitamin E on the relative risk of common cold as a function of age at 
follow-up. Participants smoking more (A) and less (B) are further divided into subgroups by 
residential neighborhood. RR indicates the relative risk of colds between the vitamin E and placebo 
arms. See Table 2 for the description of the statistical models. These versions were redrawn in 2014.
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